Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine

Bean, 1962, The treatment of chronic ulcerative colitis with 6-mercaptopurine, Med J Aust, 2, 592, 10.5694/j.1326-5377.1962.tb20590.x

Brooke, 1969, Azathioprine for Crohn's disease, Lancet, 2, 612, 10.1016/S0140-6736(69)90325-0

Stack, 1999, Immunosuppressive therapy for ulcerative colitis: results of a nation-wide survey among consultant physician members of the British Society of Gastroenterology, Aliment Pharmacol Ther, 13, 569, 10.1046/j.1365-2036.1999.00511.x

Weinshilboum, 1980, Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity, Am J Hum Genet, 32, 651

Lennard, 1989, Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism, Clin Pharmacol Ther, 46, 149, 10.1038/clpt.1989.119

Hon, 1999, Polymorphism of the thiopurine S-methyltransferase gene in African-Americans, Hum Mol Genet, 8, 371, 10.1093/hmg/8.2.371

Ameyaw, 1999, Thiopurine methyltransferase alleles in British and Ghanaian populations, Hum Mol Genet, 8, 367, 10.1093/hmg/8.2.367

Weinshilboum, 2001, Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase, Drug Metab Dispos, 29, 601

Yates, 1997, Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance, Ann Intern Med, 126, 608, 10.7326/0003-4819-126-8-199704150-00003

Otterness, 1997, Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms, Clin Pharmacol Ther, 62, 60, 10.1016/S0009-9236(97)90152-1

Krynetski, 2000, Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance, Pharmacology, 61, 136, 10.1159/000028394

Lennard, 1992, The clinical pharmacology of 6-mercaptopurine, Eur J Clin Pharmacol, 43, 329, 10.1007/BF02220605

Brogan, 1985, The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease, J Clin Immunol, 5, 204, 10.1007/BF00915512

Tiede, 2003, CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+T lymphocytes, J Clin Invest, 111, 1133, 10.1172/JCI16432

Van Os, 1996, Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration, Gut, 39, 63, 10.1136/gut.39.1.63

Elion, 1969, The comparative metabolism of Imuran and 6-mercaptopurine in man, Proc Am Assoc Cancer Res, 10, 21

Markowitz, 2000, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenterology, 119, 895, 10.1053/gast.2000.18144

Rhodes, 1971, Controlled trial of azathioprine in Crohn's disease, Lancet, 2, 1273, 10.1016/S0140-6736(71)90598-8

Willoughby, 1971, Controlled trial of azathioprine in Crohn's disease, Lancet, 2, 944, 10.1016/S0140-6736(71)90268-6

Klein, 1974, Treatment of Crohn's disease with azathioprine: a controlled evaluation, Gastroenterology, 66, 916, 10.1016/S0016-5085(74)80166-6

Summers, 1979, National Cooperative Crohn's Disease Study: results of drug treatment, Gastroenterology, 77, 847, 10.1016/0016-5085(79)90385-8

Present, 1980, Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study, N Engl J Med, 302, 981, 10.1056/NEJM198005013021801

Ewe, 1993, Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease, Gastroenterology, 105, 367, 10.1016/0016-5085(93)90709-L

Candy, 1995, A controlled double blind study of azathioprine in the management of Crohn's disease, Gut, 37, 674, 10.1136/gut.37.5.674

Oren, 1997, Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial, Am J Gastroenterol, 92, 2203

Rosenberg, 1975, A controlled trial of azathioprine in Crohn's disease, Am J Dig Dis, 20, 721, 10.1007/BF01070829

O'Donoghue, 1978, Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease, Lancet, 2, 955, 10.1016/S0140-6736(78)92524-2

Sandborn, 2000, Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease, Cochrane Database Syst Rev, 2, CD000545

Pearson, 2000, Azathioprine for maintaining remission of Crohn's disease, Cochrane Database Syst Rev, 2, CD000067

Korelitz, 1993, Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease, Am J Gastroenterol, 88, 1198

Korelitz, 1998, Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2 year multicenter trial, Gastroenterology, 114, A1011, 10.1016/S0016-5085(98)84115-2

Korelitz, 1985, Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease, Dig Dis Sci, 30, 58, 10.1007/BF01318372

Caprilli, 1975, Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis: preliminary report, Am J Dig Dis, 20, 115, 10.1007/BF01072336

Ardizzone, 2001, Azathioprine is more effective than oral 5-ASA in the treatment of steroid-dependent ulcerative colitis, Gastroenterology, 120, A127, 10.1016/S0016-5085(08)80623-3

Sood, 2003, Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis, Indian J Gastroenterol, 22, 79

Mantzaris, 2001, A prospective, randomized trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis, Gastroenterology, 120, A127, 10.1016/S0016-5085(08)80624-5

Hawthorne, 1992, Randomised controlled trial of azathioprine withdrawal in ulcerative colitis, BMJ, 305, 20, 10.1136/bmj.305.6844.20

Jewell, 1974, Azathioprine in ulcerative colitis: final report on controlled therapeutic trial, BMJ, 4, 627, 10.1136/bmj.4.5945.627

Kirk, 1982, Controlled trial of azathioprine in chronic ulcerative colitis, BMJ, 284, 1291, 10.1136/bmj.284.6325.1291

Rosenberg, 1975, A controlled trial of azathioprine in the management of chronic ulcerative colitis, Gastroenterology, 69, 96, 10.1016/S0016-5085(19)32641-1

Adler, 1990, The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis, Am J Gastroenterol, 85, 717

Ardizzone, 1997, Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis, J Clin Gastroenterol, 25, 330, 10.1097/00004836-199707000-00007

George, 1996, The long-term outcome of ulcerative colitis treated with 6-mercaptopurine, Am J Gastroenterol, 91, 1711

Cohen, 1999, Intravenous cyclosporin in ulcerative colitis: a five-year experience, Am J Gastroenterol, 94, 1587, 10.1111/j.1572-0241.1999.01149.x

Fernandez-Banares, 1996, Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis, Am J Gastroenterol, 91, 2498

Domenech, 2002, Azathioprine without oral cyclosporin in the long-term maintenance of remission induced by intravenous cyclosporin in severe, steroid-refractory ulcerative colitis, Aliment Pharmacol Ther, 16, 2061, 10.1046/j.1365-2036.2002.01385.x

Zimm, 1983, Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?, N Engl J Med, 308, 1005, 10.1056/NEJM198304283081705

Lennard, 1986, Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations, Clin Pharmacol Ther, 40, 287, 10.1038/clpt.1986.178

Lennard, 1984, Azathioprine metabolism in kidney transplant recipients, Br J Clin Pharmacol, 18, 693, 10.1111/j.1365-2125.1984.tb02531.x

Lennard, 1983, Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia, Br J Clin Pharmacol, 16, 359, 10.1111/j.1365-2125.1983.tb02178.x

Zimm, 1985, Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion, Cancer Res, 45, 1869

Lennard, 1989, Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia, J Clin Oncol, 7, 1816, 10.1200/JCO.1989.7.12.1816

Lennard, 1987, Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris, Br J Clin Pharmacol, 23, 229, 10.1111/j.1365-2125.1987.tb03034.x

Chan, 1990, Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients, J Clin Pharmacol, 30, 358, 10.1002/j.1552-4604.1990.tb03606.x

Sandborn, 1999, Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group, Gastroenterology, 117, 527, 10.1016/S0016-5085(99)70445-2

Mahadevan, 2000, Intravenous azathioprine in severe ulcerative colitis: a pilot study, Am J Gastroenterol, 95, 3463, 10.1111/j.1572-0241.2000.03362.x

Bouhnik, 1996, Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine, Lancet, 347, 215, 10.1016/S0140-6736(96)90402-X

Kim, 1999, Optimum duration of treatment with 6-mercaptopurine for Crohn's disease, Am J Gastroenterol, 94, 3254, 10.1111/j.1572-0241.1999.01532.x

Fraser, 2002, The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review, Gut, 50, 485, 10.1136/gut.50.4.485

Lemann, 2002, Randomized, double-blind, placebo-controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn's disease (CD), Gastroenterology, 122, A23

Lewis, 2000, Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma, Gastroenterology, 118, 1018, 10.1016/S0016-5085(00)70353-2

Korelitz, 1999, Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease, J Clin Gastroenterol, 28, 341, 10.1097/00004836-199906000-00011

Present, 1989, 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity, Ann Intern Med, 111, 641, 10.7326/0003-4819-111-8-641

Cheng, 2000, Are individuals with Crohn's disease who are intolerant to 6-mercaptopurine able to tolerate azathioprine?, Gastroenterology, 118, A1336, 10.1016/S0016-5085(00)81211-1

Rajapakse, 2000, Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease, Am J Gastroenterol, 95, 684, 10.1111/j.1572-0241.2000.01846.x

Haber, 1986, Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease, Gastroenterology, 91, 982, 10.1016/0016-5085(86)90703-1

Connell, 1993, Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience, Gut, 34, 1081, 10.1136/gut.34.8.1081

Colombel, 2000, Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy, Gastroenterology, 118, 1025, 10.1016/S0016-5085(00)70354-4

Dubinsky, 2000, Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease, Gastroenterology, 118, 705, 10.1016/S0016-5085(00)70140-5

Pfau, 2001, Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient, Am J Gastroenterol, 96, 895, 10.1111/j.1572-0241.2001.03672.x

Korelitz, 1999, Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease, Am J Gastroenterol, 94, 424, 10.1111/j.1572-0241.1999.871_w.x

Aberra, 2003, Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients, Gastroenterology, 125, 320, 10.1016/S0016-5085(03)00883-7

Connell, 1994, Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease, Lancet, 343, 1249, 10.1016/S0140-6736(94)92150-4

Gelb, 1983, The use of azathioprine and 6-mercaptopurine (6-MP) as immunosuppressive therapy in inflammatory bowel disease and its role in the etiology of lymphocytic lymphoma, Am J Gastroenterol, 78, 316

Larvol, 1994, Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease, N Engl J Med, 331, 883, 10.1056/NEJM199409293311321

Bickston, 1999, The relationship between infliximab treatment and lymphoma in Crohn's disease, Gastroenterology, 117, 1433, 10.1016/S0016-5085(99)70294-5

Asten, 1999, Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases, J Rheumatol, 26, 1705

Kinlen, 1985, Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment, Am J Med, 78, 44, 10.1016/0002-9343(85)90245-1

Opelz, 1993, Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients, Lancet, 342, 1514, 10.1016/S0140-6736(05)80084-4

Penn, 1974, Chemical immunosuppression and human cancer, Cancer, 34, 80

Silman, 1988, Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study, Ann Rheum Dis, 47, 988, 10.1136/ard.47.12.988

Wilkinson, 1989, Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone, Transplantation, 47, 293, 10.1097/00007890-198902000-00020

Fraser, 2002, Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine, Aliment Pharmacol Ther, 16, 1225, 10.1046/j.1365-2036.2002.01297.x

Lewis, 2001, Inflammatory bowel disease is not associated with an increased risk of lymphoma, Gastroenterology, 121, 1080, 10.1053/gast.2001.28703

Farrell, 2000, Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low, Gut, 47, 514, 10.1136/gut.47.4.514

Dayharsh, 2002, Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine, Gastroenterology, 122, 72, 10.1053/gast.2002.30328

Lennard, 1990, Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia, Lancet, 336, 225, 10.1016/0140-6736(90)91745-V

Lennard, 1987, Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations, Clin Pharmacol Ther, 41, 18, 10.1038/clpt.1987.4

Lilleyman, 1994, Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia, Lancet, 343, 1188, 10.1016/S0140-6736(94)92400-7

Colonna, 1994, The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease, Am J Gastroenterol, 89, 362

Markowitz, 1998, Relationship of leukopenia to 6-MP induced remission of Crohn's disease, J Pediatr Gastroenterol Nutr, 27, A8, 10.1097/00005176-199810000-00028

Cuffari, 1996, 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity, Gut, 39, 401, 10.1136/gut.39.3.401

Cuffari, 2001, Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease, Gut, 48, 642, 10.1136/gut.48.5.642

Achkar, 2000, 6-Thioguanine levels versus white blood cell counts in guiding 6-mercaptopurine and azathioprine therapy, Am J Gastroenterol, 95, A2491, 10.1111/j.1572-0241.2000.02632.x

Su, 2002, Measurement of 6-TG levels in patients with IBD: Are all groups identical?, Gastroenterology, 122, A78

Dubinsky, 2002, 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease, Gastroenterology, 122, 904, 10.1053/gast.2002.32420

Dubinsky, 2002, Maximizing thiopurine therapy in inflammatory bowel disease: the role of TPMT analysis and metabolite monitoring as predictors of safety and efficacy, Clinical Perspectives in Gastroenterology, 5, 343

Cuffari, 2002, Thiopurine methyltransferase (TPMT) activity influences clinical response to maintenance azathioprine therapy in patients with IBD, Gastroenterology, 122, A221

Su, 2002, The long-term benefit of therapeutic drug monitoring in IBD patients receiving AZA/6-MP, Gastroenterology, 122, A77

Lewis, 1997, Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction, Clin Pharmacol Ther, 62, 464, 10.1016/S0009-9236(97)90125-9

Lowry, 1999, Balsalazide and azathioprine or 6-mercaptopurine: evidence for a potentially serious drug interaction, Gastroenterology, 116, 1505, 10.1016/S0016-5085(99)70524-X

Szumlanski, 1995, Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine, Br J Clin Pharmacol, 39, 456, 10.1111/j.1365-2125.1995.tb04478.x

Lowry, 2001, Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide, Gut, 49, 656, 10.1136/gut.49.5.656

Woodson, 1983, Thiopurine methyltransferase: aromatic thiol substrates and inhibition by benzoic acid derivatives, Mol Pharmacol, 24, 471

Lysaa, 1996, Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide, Eur J Clin Pharmacol, 49, 393, 10.1007/BF00203784

Rosenkrantz, 1967, Azathioprine (Imuran) and pregnancy, Am J Obstet Gynecol, 97, 387, 10.1016/0002-9378(67)90503-0

Polifka, 2002, Teratogen update: azathioprine and 6-mercaptopurine, Teratology, 65, 240, 10.1002/tera.10043

Generoso, 1975, 6-mercaptopurine, an inducer of cytogenetic and dominant-lethal effects in premeiotic and early meiotic germ cells of male mice, Mutat Res, 28, 437, 10.1016/0027-5107(75)90237-7

Meistrich, 1982, Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells, Cancer Res, 42, 122

Mosesso, 1993, The genetic toxicology of 6-mercaptopurine, Mutat Res, 296, 279, 10.1016/0165-1110(93)90015-F

Oakberg, 1982, Spermatogenic stage sensitivity to 6-mercaptopurine in the mouse, Mutat Res, 94, 165, 10.1016/0027-5107(82)90179-8

Russell, 1987, Study of the base analog 6-mercaptopurine in the mouse specific-locus test, Mutat Res, 176, 47, 10.1016/0027-5107(87)90251-X

Saarikoski, 1973, Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus, Am J Obstet Gynecol, 115, 1100, 10.1016/0002-9378(73)90559-0

Davison, 1985, Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients, Br J Obstet Gynaecol, 92, 233, 10.1111/j.1471-0528.1985.tb01088.x

DeWitte, 1984, Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone, J Pediatr, 105, 625, 10.1016/S0022-3476(84)80435-7

McGeown, 1978, Cytogenetic analysis on children born of parents treated with immunosuppressive drugs, Proc Eur Dial Transplant Assoc, 15, 384

Price, 1976, Immunosuppressive drugs and the foetus, Transplantation, 21, 294, 10.1097/00007890-197604000-00004

Erkman, 1972, Azathioprine therapy complicated by pregnancy, Obstet Gynecol, 40, 708

Farber, 1976, Successful pregnancy renal transplantation, Obstet Gynecol, 48, 2S

Hou, 1989, Pregnancy in organ transplant recipients, Med Clin North Am, 73, 667, 10.1016/S0025-7125(16)30665-4

Huynh, 1994, Outcomes of pregnancy and the management of immunosuppressive agents to minimize fetal risks in organ transplant patients, Ann Pharmacother, 28, 1355

Meehan, 1987, Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy, J Rheumatol, 14, 252

Alstead, 1990, Safety of azathioprine in pregnancy in inflammatory bowel disease, Gastroenterology, 99, 443, 10.1016/0016-5085(90)91027-4

Francella, 2003, The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study, Gastroenterology, 124, 9, 10.1053/gast.2003.50014

Zlatanic, 2003, Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease, J Clin Gastroenterol, 36, 303, 10.1097/00004836-200304000-00005

Golby, 1970, Fertility after renal transplantation, Transplantation, 10, 201, 10.1097/00007890-197009000-00001

Penn, 1971, Parenthood in renal homograft recipients, JAMA, 216, 1755, 10.1001/jama.216.11.1755

Lingardh, 1974, Fertility in men after renal transplantation, Acta Chir Scand, 140, 494